1. A method of reducing the number of B-cells or treating a disease or disorder associated with abnormal B-cell activity in an individual who has or is suspected to have a disease or disorder, comprising treating the individual with: i) a therapeutically effective amount of a CD37-specific binder molecules； ii) a therapeutically effective amount of an mTOR or PI3K inhibitor； and iii) a therapeutically effective amount of a CD-20 specific binding molecule, cytokine, chemokine, growth factor, chemotherapeutic medium Dstv or radiotherapeutic means. 2. The method of claim 1, wherein the method comprises administering an mTOR inhibitor to an individual. The method of claim 2, wherein the mTOR inhibitor is sirolimus, temsirolimus or torquinib. The method of claim 2, wherein the mTOR inhibitor is deforolimus, everolimus, tacrolimus, zotarolimus, curcumin or farnesylthiosalicylic acid. The method of claim 1, wherein the method comprises administering to the individual a PI3K.6 inhibitor. The method of claim 5, wherein the PI3K inhibitor is a P110δ-specific inhibitor. The method of claim 1, wherein the CD37-specific binding molecule is a CD37-specific antibody, or an antigen binding portion thereof, or a CD37-specific binding protein. The method of claim 1, wherein the CD37-specific binding molecule is a humanized antibody, or an antigen binding part thereof, or a humanized CD37-specific binding protein. The method of claim 1, wherein the CD37-specific binding molecule is a humanized CD37-specific binding protein containing the amino acid sequence of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 52, 60, 80, 82, 84, 86 or1. Способ уменьшения количества B-клеток или лечения заболевания или расстройства, связанного с аномальной активностью B-клеток, у индивидуума, у которого имеется или предполагается наличие заболевания или расстройства, включающий лечение индивидуума с помощью:i) терапевтически эффективного количества CD37-сп
